BRTX Share Price Performance
US$0.19
-1.39 (-87.87%)
98.9% undervalued intrinsic discount
US$18.00
Fair Value
Price US$0.19
AnalystHighTarget US$18.00
AnalystConsensusTarget US$13.00
AnalystLowTarget US$8.00
Fair ValueUS$18.00
Share Pricen/a
BioRestorative Therapies, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
BRTX Community Narratives
AN
Fair Value
·Fair Value US$18 98.9% undervalued intrinsic discount
Regenerative Cell Therapies And BioCosmeceuticals Will Reshape Long Term Value Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$13 98.5% undervalued intrinsic discount
Regenerative Therapies And Obesity Trends Will Drive Long Term Earnings Upside
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value US$8 97.6% undervalued intrinsic discount
Obesity Market And Spine Therapy Risks May Gradually Give Way To Long-Term Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Regenerative Cell Therapies And BioCosmeceuticals Will Reshape Long Term Value Potential
Catalysts About BioRestorative Therapies BioRestorative Therapies is a biotechnology company developing cell based treatments for chronic lumbar disc disease, obesity and related metabolic disorders, alongside a growing BioCosmeceuticals product line. What are the underlying business or industry changes driving this perspective?Read more
AN
US$18
98.9% undervalued intrinsic discount
Fair Value
Profit Margin
69.99%
Future PE
2.08x
Price in 2029
US$22.07
Regenerative Therapies And Obesity Trends Will Drive Long Term Earnings Upside
Catalysts About BioRestorative Therapies BioRestorative Therapies is a clinical stage biotechnology company developing cell based therapies for chronic lumbar disc disease and metabolic disorders, while commercializing exosome based BioCosmeceutical products. What are the underlying business or industry changes driving this perspective?Read more
AN
US$13
98.5% undervalued intrinsic discount
Fair Value
Profit Margin
39.97%
Future PE
6.78x
Price in 2028
US$15.93
Obesity Market And Spine Therapy Risks May Gradually Give Way To Long-Term Potential
Catalysts About BioRestorative Therapies BioRestorative Therapies is a clinical stage biotechnology company developing cell based therapies and cosmeceutical products targeting spine disease, obesity and aesthetic applications. What are the underlying business or industry changes driving this perspective?Read more
AN
US$8
97.6% undervalued intrinsic discount
Fair Value
Profit Margin
0.16%
Future PE
125.21x
Price in 2028
US$0.1
Trending Discussion
Recently Updated Narratives
AN
Regenerative Cell Therapies And BioCosmeceuticals Will Reshape Long Term Value Potential
Fair Value: US$18 98.9% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regenerative Therapies And Obesity Trends Will Drive Long Term Earnings Upside
Fair Value: US$13 98.5% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Obesity Market And Spine Therapy Risks May Gradually Give Way To Long-Term Potential
Fair Value: US$8 97.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BioRestorative Therapies, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -0.43
- 92.09%
- -3,089.55%
- 0%
About BRTX
- Founded
- n/a
- Employees
- 14
- CEO
- WebsiteView website
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
